17 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
at chronic spontaneous urticaria, or CSU, and HS.
We are also developing IFX002, a life-cycle management product for vilobelimab, which is currently … see this project as life-cycle management for vilobelimab and are conducting pre-clinical development work to get closer to the possible start
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
life-cycle approach For optimized use in chronic inflammatory indications various Additional chronic indications in I&I including neurology
6-K
EX-99.2
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
IFX002 to be a life-cycle management product to vilobelimab, given the long remaining patent life of IFX002.
Financial highlights
As of March 31
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Mar 24
Corporate Presentation March 2024
5:00pm
in 2025 other immuno-dermatology Additional indications in immuno-dermatology vilobelimab life-cycle approach For optimized use in chronic
424B5
24pdj3h3
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
voukdfwtj158 50c
30 Jun 23
Shelf registration (foreign)
4:06pm
424B5
l2i5wzw
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
66jmb
11 Apr 23
Prospectus supplement for primary offering
4:11pm
20-F/A
q7fgsu4qy
29 Mar 19
Annual report (foreign) (amended)
4:23pm
424B4
5bbsbg
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
yfhjjy4 giiwf8x
2 May 18
Registration statement (foreign)
7:10am
20-F
gfym877d3
29 Mar 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next